Loading…
Eli Lilly and Company is projected to rise to $1,245.49 by 2027, a +15% move from its current price of $1,082.92. LLY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1,063.96 | $1,083.13 | $1,102.65 | +0.02% |
| May 30 | $1,056.32 | $1,083.34 | $1,111.06 | +0.04% |
| May 31 | $1,050.54 | $1,083.55 | $1,117.60 | +0.06% |
| Jun 1 | $1,045.73 | $1,083.76 | $1,123.18 | +0.08% |
| Jun 2 | $1,041.53 | $1,083.98 | $1,128.15 | +0.10% |
| Jun 3 | $1,037.77 | $1,084.19 | $1,132.68 | +0.12% |
| Jun 4 | $1,034.34 | $1,084.40 | $1,136.88 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1,034.34 | $1,084.40 | $1,136.88 | +0.14% |
| Week 2 | $1,015.68 | $1,085.88 | $1,160.93 | +0.27% |
| Week 3 | $1,001.90 | $1,087.36 | $1,180.11 | +0.41% |
| Week 4 | $990.65 | $1,088.85 | $1,196.78 | +0.55% |
| Week 5 | $980.99 | $1,090.33 | $1,211.86 | +0.68% |
| Week 6 | $972.47 | $1,091.82 | $1,225.82 | +0.82% |
| Week 7 | $964.81 | $1,093.31 | $1,238.93 | +0.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc.
for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron.
Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company (LLY) is a healthcare stock trading at $1,065.00 per share with a market capitalization of $949.7B. It is ranked 12 by market cap among peers. The current price sits within a broader trend of steady growth reflected in a long-term forecast that envisions substantial upside over the coming years.
A major floor 28.5% below — a decisive break under it would weaken the trend.
The nearest floor, 21.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 14.3% above — clearing it would confirm fresh momentum.
Key LLY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LLY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1,054.64 | Buy | $1,057.44 | Buy |
| MA 10 | $1,031.01 | Buy | $1,034.49 | Buy |
| MA 20 | $994.17 | Buy | $1,004.23 | Buy |
| MA 50 | $946.80 | Buy | $977.73 | Buy |
| MA 100 | $991.98 | Buy | $970.57 | Buy |
| MA 200 | $932.66 | Buy | $940.58 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 70.67 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 158.01 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 9.53 | Buy |
| ROC (12) | 14.18 | Buy |
| Bollinger %B (20,2) | 0.94 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 94.21 | Buy |
| Ultimate (7,14,28) | 77.31 | Sell |
| Momentum (10) | 93.05 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 1081.66 | Buy |
| ADX (14) | 23.09 | Buy |
| ATR (14) | 16.93 | Info |
The 30-day technical picture shows bullish sentiment with RSI(14) at 70 and a bullish posture indicated by the current price in relation to key moving averages. The SMA50 is $943.33 and the SMA200 is $928.25, framing a constructive trend. Support sits at $851.21 and resistance at $1,065.00, with a 30-day range of $941.67 to $1,204.48.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $851.21 | $1,082.92 | $1,480.28 | 0% | Neutral | |
| $1,017.48 | $1,245.49 | $1,595.84 | +15% | Neutral | |
| $1,104.52 | $1,376.71 | $1,810.07 | +27% | Bullish | |
| $1,253.44 | $1,586.00 | $2,128.62 | +46% | Bullish | |
| $1,324.10 | $1,697.72 | $2,318.89 | +57% | Bullish | |
| $1,577.71 | $2,047.34 | $2,839.99 | +89% | Bullish | |
| $1,793.75 | $2,353.75 | $3,310.94 | +117% | Bullish | |
| $1,857.58 | $2,462.99 | $3,508.99 | +127% | Bullish | |
| $2,008.32 | $2,689.17 | $3,876.60 | +148% | Bullish | |
| $2,044.56 | $2,763.46 | $4,027.68 | +155% | Bullish | |
| $3,118.36 | $4,395.30 | $6,711.23 | +306% | Bullish | |
| $5,277.04 | $7,975.80 | $13,050.57 | +637% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $851.21 | $1,082.92 | $1,267.28 | +0.00% |
| June 2026 | $926.08 | $1,080.31 | $1,284.70 | -0.24% |
| July 2026 | $939.54 | $1,102.34 | $1,323.29 | +2.04% |
| August 2026 | $972.57 | $1,146.24 | $1,385.99 | +3.98% |
| September 2026 | $980.43 | $1,159.79 | $1,410.71 | +1.18% |
| October 2026 | $976.82 | $1,159.47 | $1,417.92 | -0.03% |
| November 2026 | $994.16 | $1,183.59 | $1,454.24 | +2.08% |
| December 2026 | $1,004.60 | $1,199.44 | $1,480.28 | +1.34% |
Click any year to see its month-by-month LLY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The LLY price prediction for 2026 points to an average of $1,082.92 (low $851.21, high $1,480.28) — a potential gain of 0% on today's $1,082.92. Price action looks broadly range-bound.
In 2027, LLY is projected to trade between $1,017.48 and $1,595.84, averaging $1,245.49 — a potential gain of +15% from today's $1,082.92. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
Eli Lilly and Company's 2028 outlook centres on $1,376.71, within a $1,104.52 to $1,810.07 range. That is up +11% on the projected 2027 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2029, LLY could reach as high as $2,128.62, with a base case around $1,586.00 and support toward $1,253.44 — roughly +46% from $1,082.92. Buyers look set to stay in control over this stretch.
Expect LLY to range from $1,324.10 to $2,318.89 through 2030. The $1,697.72 average target implies a +57% move from current prices. That is up +7% on the projected 2029 average. Momentum favours further upside here.
The LLY price prediction for 2031 points to an average of $2,047.34 (low $1,577.71, high $2,839.99) — a potential gain of +89% on today's $1,082.92. Buyers look set to stay in control over this stretch.
In 2032, LLY is projected to trade between $1,793.75 and $3,310.94, averaging $2,353.75 — a potential gain of +117% from today's $1,082.92. That is up +15% on the projected 2031 average. Momentum favours further upside here.
Eli Lilly and Company's 2033 outlook centres on $2,462.99, within a $1,857.58 to $3,508.99 range. That is up +5% on the projected 2032 average. That marks a +127% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, LLY could reach as high as $3,876.60, with a base case around $2,689.17 and support toward $2,008.32 — roughly +148% from $1,082.92. Momentum favours further upside here.
Expect LLY to range from $2,044.56 to $4,027.68 through 2035. The $2,763.46 average target implies a +155% move from current prices. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The LLY price prediction for 2040 points to an average of $4,395.30 (low $3,118.36, high $6,711.23) — a potential gain of +306% on today's $1,082.92. Momentum favours further upside here.
In 2050, LLY is projected to trade between $5,277.04 and $13,050.57, averaging $7,975.80 — a potential gain of +637% from today's $1,082.92. That is up +81% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LLY today (≈ 0.923429 LLY) could be worth
$7,365.09
+$6,365.09 (+637%) by 2050 · US Dollar
Based on the average projected LLY price of $7,975.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LLYwould be worth at today's price.
$1,000 invested in LLY on May 27, 2025 (≈ 1.378892 LLY) would be worth
$1,493.23
+$493.23 (+49.3%) today · 1.49× · US Dollar
Based on a LLY entry price of $725.22 vs. today's $1,082.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1,018.87 | $1,062.86 | +6.3% |
| 1 month ago | $868.27 | $1,247.22 | +24.7% |
| 3 months ago | $1,022.02 | $1,059.59 | +6.0% |
| 6 months ago | $1,075.47 | $1,006.93 | +0.7% |
| 1 year ago | $725.22 | $1,493.23 | +49.3% |
| All time (5.0y) ago | $198.42 | $5,457.72 | +445.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LLY forecast.
Our base-case forecast reaches $2,200.00 around 2032.
Implied market cap at $2,200.00: $1.96T
The multi-year forecast points to a strong, bullish trajectory after a neutral start. For 2026 the avg price is $1,065.00 with a min of $851.21 and a max of $1,447.70 (ROI 0, sentiment NEUTRAL). By 2027 the avg grows to $1,208.52 with a max of $1,549.10 (ROI 13.5, sentiment NEUTRAL).
From 2028 onward, the outlook turns bullish, with 2028 avg $1,333.24 and 2029 avg $1,517.15, rising to 2030 avg $1,607.81 (ROI 51, sentiment BULLISH). The path continues through 2031 with avg $1,938.25 (ROI 82) and 2032 with avg $2,216.71 (ROI 108.1), then 2033 avg $2,306.39 (ROI 116.6) and 2034 avg $2,517.72 (ROI 136.4), and 2035 avg $2,569.21 (ROI 141.2). The forecast accelerates to 2040 with avg $4,059.53 (ROI 281.2) and to 2050 with avg $7,202.51 (ROI 576.3).
Overall, the long-term view is bullish, reflecting a substantial potential increase in value, while noting that these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1,607.81, with a min of $1,253.76 and a max of $2,196.57. The projected ROI is 51% and the sentiment is BULLISH.
The forecast shows a bullish sentiment from 2028 onward, with rising average prices: $1,333.24 in 2028, $1,517.15 in 2029, $1,607.81 in 2030, and up to $7,202.51 by 2050, with progressively higher ROIs (e.g., 281.2% in 2040 and 576.3% in 2050). These are estimates and not guarantees.
Yes. The max forecast reaches $6,199.22 in 2040, based on the provided numbers. Earlier years peak below that, with 2035 max $3,745.10 and 2040 max $6,199.22.
The current price is $1,065.00 per share, and the market capitalization is $949.7B. The company is ranked 12 by market cap.
The 30-day picture shows bullish sentiment with RSI(14) at 70, a SMA50 of $943.33, and a SMA200 of $928.25. The 30-day range runs from $941.67 to $1,204.48, with support at $851.21 and resistance at $1,065.00.
Eli Lilly and Company Community Discussion
0Share your Eli Lilly and Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.